We are #2 because we put KIDS FIRST
This technology utilizes methods and compositions related to reducing the risk of or preventing fetal wastage by administering CXCR3 inhibitors.
IRAK1 is a drugable target for treatment of MDS, and IRAK1/BCL2 inhibitors synergistically co-treat MDS.
A Growing Pipeline of Innovations
Find out how we are building the research-to-market bridge in the latest Research Horizons
Partner with Us
View our innovation portfolio
A New Funding Opportunity & Research Collaboration with BridgeBio Pharma
November 2, 2018